APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Homozygous Familial Hypercholesterolemia Treatment

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Homozygous Familial Hypercholesterolemia Treatment Market Outlook and Growth Opportunities 2026

Report ID 173999010422 December 2025190 pages

Choose your research edition.

Industry ResearchHomozygous Familial Hypercholesterolemia Treatment Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Homozygous Familial Hypercholesterolemia Treatment Industry Growth and Trends Forecast to 203291 pages · $3,450 USDMarket StructureGlobal Homozygous Familial Hypercholesterolemia Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Homozygous Familial Hypercholesterolemia Treatment Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Homozygous Familial Hypercholesterolemia Treatment Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Homozygous Familial Hypercholesterolemia Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Homozygous Familial Hypercholesterolemia Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Homozygous Familial Hypercholesterolemia Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Homozygous Familial Hypercholesterolemia Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Homozygous Familial Hypercholesterolemia Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Homozygous Familial Hypercholesterolemia Treatment market include The Medicines Company, RegenxBio Inc, Regeneron Pharmaceuticals Inc, LipimetiX Development Inc, Gemphire Therapeutics Inc, Daewoong Co Ltd and CymaBay Therapeutics Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Homozygous Familial Hypercholesterolemia Treatment market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Homozygous Familial Hypercholesterolemia Treatment and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Homozygous Familial Hypercholesterolemia Treatment sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Homozygous Familial Hypercholesterolemia Treatment market size, projected growth trends, production technologies, key applications, and end-use industries.

Homozygous Familial Hypercholesterolemia Treatment Segment by Company

The Medicines Company

RegenxBio Inc

Regeneron Pharmaceuticals Inc

LipimetiX Development Inc

Gemphire Therapeutics Inc

Daewoong Co Ltd

CymaBay Therapeutics Inc

Homozygous Familial Hypercholesterolemia Treatment Segment by Type

Alirocumab

Evinacumab

AEM-2814

AEM-2802

Others

Homozygous Familial Hypercholesterolemia Treatment Segment by Application

Clinic

Hospital

Others

Homozygous Familial Hypercholesterolemia Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Homozygous Familial Hypercholesterolemia Treatment status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Homozygous Familial Hypercholesterolemia Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Homozygous Familial Hypercholesterolemia Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze Homozygous Familial Hypercholesterolemia Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Homozygous Familial Hypercholesterolemia Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Homozygous Familial Hypercholesterolemia Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Homozygous Familial Hypercholesterolemia Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Homozygous Familial Hypercholesterolemia Treatment market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Homozygous Familial Hypercholesterolemia Treatment industry.

Chapter 3: Detailed analysis of Homozygous Familial Hypercholesterolemia Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Homozygous Familial Hypercholesterolemia Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Homozygous Familial Hypercholesterolemia Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Homozygous Familial Hypercholesterolemia Treatment Industry Trends Table 2. Homozygous Familial Hypercholesterolemia Treatment Industry Drivers Table 3. Homozygous Familial Hypercholesterolemia Treatment Industry Opportunities and Challenges Table 4. Homozygous Familial Hypercholesterolemia Treatment Industry Restraints Table 5. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Share by Company (2021-2026) Table 7. Global Homozygous Familial Hypercholesterolemia Treatment Sales Volume by Company (k units) & (2021-2026) Table 8. Global Homozygous Familial Hypercholesterolemia Treatment Sales Volume Share by Company (2021-2026) Table 9. Global Homozygous Familial Hypercholesterolemia Treatment Average Price (US$/unit) of Company (2021-2026) Table 10. Global Homozygous Familial Hypercholesterolemia Treatment Company Ranking, (2024-2026) & (USD Million) Table 11. Global Homozygous Familial Hypercholesterolemia Treatment Key Company Manufacturing Base & Headquarters Table 12. Global Homozygous Familial Hypercholesterolemia Treatment Company, Product Type & Application Table 13. Global Homozygous Familial Hypercholesterolemia Treatment Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Homozygous Familial Hypercholesterolemia Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Alirocumab Table 18. Significant Companies of Evinacumab Table 19. Significant Companies of AEM-2814 Table 20. Significant Companies of AEM-2802 Table 21. Significant Companies of Others Table 22. Global Homozygous Familial Hypercholesterolemia Treatment Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 23. Global Homozygous Familial Hypercholesterolemia Treatment Sales Volume by Type (2021-2026) & (k units) Table 24. Global Homozygous Familial Hypercholesterolemia Treatment Sales Volume by Type (2027-2032) & (k units) Table 25. Global Homozygous Familial Hypercholesterolemia Treatment Sales Volume Share by Type (2021-2026) Table 26. Global Homozygous Familial Hypercholesterolemia Treatment Sales Volume Share by Type (2027-2032) Table 27. Global Homozygous Familial Hypercholesterolemia Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Homozygous Familial Hypercholesterolemia Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Homozygous Familial Hypercholesterolemia Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type (2021-2026) Table 31. Global Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Clinic Table 33. Significant Companies of Hospital Table 34. Significant Companies of Others Table 35. Global Homozygous Familial Hypercholesterolemia Treatment Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 36. Global Homozygous Familial Hypercholesterolemia Treatment Sales Volume by Application (2021-2026) & (k units) Table 37. Global Homozygous Familial Hypercholesterolemia Treatment Sales Volume by Application (2027-2032) & (k units) Table 38. Global Homozygous Familial Hypercholesterolemia Treatment Sales Volume Share by Application (2021-2026) Table 39. Global Homozygous Familial Hypercholesterolemia Treatment Sales Volume Share by Application (2027-2032) Table 40. Global Homozygous Familial Hypercholesterolemia Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Homozygous Familial Hypercholesterolemia Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Homozygous Familial Hypercholesterolemia Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application (2021-2026) Table 44. Global Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application (2027-2032) Table 45. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 46. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Region (2021-2026) & (k units) Table 47. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Region (2021-2026) Table 48. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Region (2027-2032) & (k units) Table 49. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Region (2027-2032) Table 50. Global Homozygous Familial Hypercholesterolemia Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Homozygous Familial Hypercholesterolemia Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Region (2021-2026) Table 53. Global Homozygous Familial Hypercholesterolemia Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Region (2027-2032) Table 55. Global Homozygous Familial Hypercholesterolemia Treatment Market Average Price (US$/unit) by Region (2021-2026) Table 56. Global Homozygous Familial Hypercholesterolemia Treatment Market Average Price (US$/unit) by Region (2027-2032) Table 57. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 58. Global Homozygous Familial Hypercholesterolemia Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2021-2026) & (k units) Table 60. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Country (2021-2026) Table 61. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2027-2032) & (k units) Table 62. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Country (2027-2032) Table 63. Global Homozygous Familial Hypercholesterolemia Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Homozygous Familial Hypercholesterolemia Treatment Sales Value Market Share by Country (2021-2026) Table 65. Global Homozygous Familial Hypercholesterolemia Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Homozygous Familial Hypercholesterolemia Treatment Sales Value Market Share by Country (2027-2032) Table 67. The Medicines Company Company Information Table 68. The Medicines Company Business Overview Table 69. The Medicines Company Homozygous Familial Hypercholesterolemia Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 70. The Medicines Company Homozygous Familial Hypercholesterolemia Treatment Product Portfolio Table 71. The Medicines Company Recent Development Table 72. RegenxBio Inc Company Information Table 73. RegenxBio Inc Business Overview Table 74. RegenxBio Inc Homozygous Familial Hypercholesterolemia Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 75. RegenxBio Inc Homozygous Familial Hypercholesterolemia Treatment Product Portfolio Table 76. RegenxBio Inc Recent Development Table 77. Regeneron Pharmaceuticals Inc Company Information Table 78. Regeneron Pharmaceuticals Inc Business Overview Table 79. Regeneron Pharmaceuticals Inc Homozygous Familial Hypercholesterolemia Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 80. Regeneron Pharmaceuticals Inc Homozygous Familial Hypercholesterolemia Treatment Product Portfolio Table 81. Regeneron Pharmaceuticals Inc Recent Development Table 82. LipimetiX Development Inc Company Information Table 83. LipimetiX Development Inc Business Overview Table 84. LipimetiX Development Inc Homozygous Familial Hypercholesterolemia Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 85. LipimetiX Development Inc Homozygous Familial Hypercholesterolemia Treatment Product Portfolio Table 86. LipimetiX Development Inc Recent Development Table 87. Gemphire Therapeutics Inc Company Information Table 88. Gemphire Therapeutics Inc Business Overview Table 89. Gemphire Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 90. Gemphire Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Product Portfolio Table 91. Gemphire Therapeutics Inc Recent Development Table 92. Daewoong Co Ltd Company Information Table 93. Daewoong Co Ltd Business Overview Table 94. Daewoong Co Ltd Homozygous Familial Hypercholesterolemia Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 95. Daewoong Co Ltd Homozygous Familial Hypercholesterolemia Treatment Product Portfolio Table 96. Daewoong Co Ltd Recent Development Table 97. CymaBay Therapeutics Inc Company Information Table 98. CymaBay Therapeutics Inc Business Overview Table 99. CymaBay Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 100. CymaBay Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Product Portfolio Table 101. CymaBay Therapeutics Inc Recent Development Table 102. Key Raw Materials Table 103. Raw Materials Key Suppliers Table 104. Homozygous Familial Hypercholesterolemia Treatment Distributors List Table 105. Homozygous Familial Hypercholesterolemia Treatment Customers List Table 106. Research Programs/Design for This Report Table 107. Authors List of This Report Table 108. Secondary Sources Table 109. Primary Sources List of Figures Figure 1. Homozygous Familial Hypercholesterolemia Treatment Product Image Figure 2. Global Homozygous Familial Hypercholesterolemia Treatment Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Homozygous Familial Hypercholesterolemia Treatment Sales Value (2021-2032) & (US$ Million) Figure 4. Global Homozygous Familial Hypercholesterolemia Treatment Sales (2021-2032) & (k units) Figure 5. Global Homozygous Familial Hypercholesterolemia Treatment Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Homozygous Familial Hypercholesterolemia Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Alirocumab Image Figure 10. Evinacumab Image Figure 11. AEM-2814 Image Figure 12. AEM-2802 Image Figure 13. Others Image Figure 14. Global Homozygous Familial Hypercholesterolemia Treatment Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Homozygous Familial Hypercholesterolemia Treatment Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Homozygous Familial Hypercholesterolemia Treatment Sales Volume Share by Type (2021-2032) Figure 17. Global Homozygous Familial Hypercholesterolemia Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Homozygous Familial Hypercholesterolemia Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type (2021-2032) Figure 20. Clinic Image Figure 21. Hospital Image Figure 22. Others Image Figure 23. Global Homozygous Familial Hypercholesterolemia Treatment Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global Homozygous Familial Hypercholesterolemia Treatment Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Homozygous Familial Hypercholesterolemia Treatment Sales Volume Share by Application (2021-2032) Figure 26. Global Homozygous Familial Hypercholesterolemia Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Homozygous Familial Hypercholesterolemia Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application (2021-2032) Figure 29. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 30. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Homozygous Familial Hypercholesterolemia Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Homozygous Familial Hypercholesterolemia Treatment Sales Value (2021-2032) & (US$ Million) Figure 34. North America Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Homozygous Familial Hypercholesterolemia Treatment Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Homozygous Familial Hypercholesterolemia Treatment Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Homozygous Familial Hypercholesterolemia Treatment Sales Value (2021-2032) & (US$ Million) Figure 40. South America Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Homozygous Familial Hypercholesterolemia Treatment Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Homozygous Familial Hypercholesterolemia Treatment Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Alirocumab
  • Evinacumab
  • AEM-2814
  • AEM-2802
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • The Medicines Company
  • RegenxBio Inc
  • Regeneron Pharmaceuticals Inc
  • LipimetiX Development Inc
  • Gemphire Therapeutics Inc
  • Daewoong Co Ltd
  • CymaBay Therapeutics Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Homozygous Familial Hypercholesterolemia Treatment Sales Value (2021-2032)
  4. 1.2.2 Global Homozygous Familial Hypercholesterolemia Treatment Sales Volume (2021-2032)
  5. 1.2.3 Global Homozygous Familial Hypercholesterolemia Treatment Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Homozygous Familial Hypercholesterolemia Treatment Market Dynamics
  1. 2.1 Homozygous Familial Hypercholesterolemia Treatment Industry Trends
  2. 2.2 Homozygous Familial Hypercholesterolemia Treatment Industry Drivers
  3. 2.3 Homozygous Familial Hypercholesterolemia Treatment Industry Opportunities and Challenges
  4. 2.4 Homozygous Familial Hypercholesterolemia Treatment Industry Restraints
3 Homozygous Familial Hypercholesterolemia Treatment Market by Company
  1. 3.1 Global Homozygous Familial Hypercholesterolemia Treatment Company Revenue Ranking in 2025
  2. 3.2 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Company (2021-2026)
  3. 3.3 Global Homozygous Familial Hypercholesterolemia Treatment Sales Volume by Company (2021-2026)
  4. 3.4 Global Homozygous Familial Hypercholesterolemia Treatment Average Price by Company (2021-2026)
  5. 3.5 Global Homozygous Familial Hypercholesterolemia Treatment Company Ranking (2024-2026)
  6. 3.6 Global Homozygous Familial Hypercholesterolemia Treatment Company Manufacturing Base and Headquarters
  7. 3.7 Global Homozygous Familial Hypercholesterolemia Treatment Company Product Type and Application
  8. 3.8 Global Homozygous Familial Hypercholesterolemia Treatment Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Homozygous Familial Hypercholesterolemia Treatment Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Homozygous Familial Hypercholesterolemia Treatment Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Homozygous Familial Hypercholesterolemia Treatment Market by Type
  1. 4.1 Homozygous Familial Hypercholesterolemia Treatment Type Introduction
  2. 4.1.1 Alirocumab
  3. 4.1.2 Evinacumab
  4. 4.1.3 AEM-2814
  5. 4.1.4 AEM-2802
  6. 4.1.5 Others
  7. 4.2 Global Homozygous Familial Hypercholesterolemia Treatment Sales Volume by Type
  8. 4.2.1 Global Homozygous Familial Hypercholesterolemia Treatment Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Homozygous Familial Hypercholesterolemia Treatment Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Homozygous Familial Hypercholesterolemia Treatment Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Homozygous Familial Hypercholesterolemia Treatment Sales Value by Type
  12. 4.3.1 Global Homozygous Familial Hypercholesterolemia Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Homozygous Familial Hypercholesterolemia Treatment Sales Value by Type (2021-2032)
  14. 4.3.3 Global Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type (2021-2032)
5 Homozygous Familial Hypercholesterolemia Treatment Market by Application
  1. 5.1 Homozygous Familial Hypercholesterolemia Treatment Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Homozygous Familial Hypercholesterolemia Treatment Sales Volume by Application
  6. 5.2.1 Global Homozygous Familial Hypercholesterolemia Treatment Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Homozygous Familial Hypercholesterolemia Treatment Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Homozygous Familial Hypercholesterolemia Treatment Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Homozygous Familial Hypercholesterolemia Treatment Sales Value by Application
  10. 5.3.1 Global Homozygous Familial Hypercholesterolemia Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Homozygous Familial Hypercholesterolemia Treatment Sales Value by Application (2021-2032)
  12. 5.3.3 Global Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application (2021-2032)
6 Homozygous Familial Hypercholesterolemia Treatment Regional Sales and Value Analysis
  1. 6.1 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Region (2021-2032)
  3. 6.2.1 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Region: 2021-2026
  4. 6.2.2 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Region (2027-2032)
  5. 6.3 Global Homozygous Familial Hypercholesterolemia Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Homozygous Familial Hypercholesterolemia Treatment Sales Value by Region (2021-2032)
  7. 6.4.1 Global Homozygous Familial Hypercholesterolemia Treatment Sales Value by Region: 2021-2026
  8. 6.4.2 Global Homozygous Familial Hypercholesterolemia Treatment Sales Value by Region (2027-2032)
  9. 6.5 Global Homozygous Familial Hypercholesterolemia Treatment Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Homozygous Familial Hypercholesterolemia Treatment Sales Value (2021-2032)
  12. 6.6.2 North America Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Homozygous Familial Hypercholesterolemia Treatment Sales Value (2021-2032)
  15. 6.7.2 Europe Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Homozygous Familial Hypercholesterolemia Treatment Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Homozygous Familial Hypercholesterolemia Treatment Sales Value (2021-2032)
  21. 6.9.2 South America Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Country, 2025 VS 2032
7 Homozygous Familial Hypercholesterolemia Treatment Country-level Sales and Value Analysis
  1. 7.1 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Homozygous Familial Hypercholesterolemia Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2021-2032)
  4. 7.3.1 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2021-2026)
  5. 7.3.2 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2027-2032)
  6. 7.4 Global Homozygous Familial Hypercholesterolemia Treatment Sales Value by Country (2021-2032)
  7. 7.4.1 Global Homozygous Familial Hypercholesterolemia Treatment Sales Value by Country (2021-2026)
  8. 7.4.2 Global Homozygous Familial Hypercholesterolemia Treatment Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Homozygous Familial Hypercholesterolemia Treatment Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Homozygous Familial Hypercholesterolemia Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 The Medicines Company
  2. 8.1.1 The Medicines Company Company Information
  3. 8.1.2 The Medicines Company Business Overview
  4. 8.1.3 The Medicines Company Homozygous Familial Hypercholesterolemia Treatment Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 The Medicines Company Homozygous Familial Hypercholesterolemia Treatment Product Portfolio
  6. 8.1.5 The Medicines Company Recent Developments
  7. 8.2 RegenxBio Inc
  8. 8.2.1 RegenxBio Inc Company Information
  9. 8.2.2 RegenxBio Inc Business Overview
  10. 8.2.3 RegenxBio Inc Homozygous Familial Hypercholesterolemia Treatment Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 RegenxBio Inc Homozygous Familial Hypercholesterolemia Treatment Product Portfolio
  12. 8.2.5 RegenxBio Inc Recent Developments
  13. 8.3 Regeneron Pharmaceuticals Inc
  14. 8.3.1 Regeneron Pharmaceuticals Inc Company Information
  15. 8.3.2 Regeneron Pharmaceuticals Inc Business Overview
  16. 8.3.3 Regeneron Pharmaceuticals Inc Homozygous Familial Hypercholesterolemia Treatment Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Regeneron Pharmaceuticals Inc Homozygous Familial Hypercholesterolemia Treatment Product Portfolio
  18. 8.3.5 Regeneron Pharmaceuticals Inc Recent Developments
  19. 8.4 LipimetiX Development Inc
  20. 8.4.1 LipimetiX Development Inc Company Information
  21. 8.4.2 LipimetiX Development Inc Business Overview
  22. 8.4.3 LipimetiX Development Inc Homozygous Familial Hypercholesterolemia Treatment Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 LipimetiX Development Inc Homozygous Familial Hypercholesterolemia Treatment Product Portfolio
  24. 8.4.5 LipimetiX Development Inc Recent Developments
  25. 8.5 Gemphire Therapeutics Inc
  26. 8.5.1 Gemphire Therapeutics Inc Company Information
  27. 8.5.2 Gemphire Therapeutics Inc Business Overview
  28. 8.5.3 Gemphire Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Gemphire Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Product Portfolio
  30. 8.5.5 Gemphire Therapeutics Inc Recent Developments
  31. 8.6 Daewoong Co Ltd
  32. 8.6.1 Daewoong Co Ltd Company Information
  33. 8.6.2 Daewoong Co Ltd Business Overview
  34. 8.6.3 Daewoong Co Ltd Homozygous Familial Hypercholesterolemia Treatment Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Daewoong Co Ltd Homozygous Familial Hypercholesterolemia Treatment Product Portfolio
  36. 8.6.5 Daewoong Co Ltd Recent Developments
  37. 8.7 CymaBay Therapeutics Inc
  38. 8.7.1 CymaBay Therapeutics Inc Company Information
  39. 8.7.2 CymaBay Therapeutics Inc Business Overview
  40. 8.7.3 CymaBay Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 CymaBay Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Product Portfolio
  42. 8.7.5 CymaBay Therapeutics Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Homozygous Familial Hypercholesterolemia Treatment Value Chain Analysis
  2. 9.1.1 Homozygous Familial Hypercholesterolemia Treatment Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Homozygous Familial Hypercholesterolemia Treatment Sales Mode & Process
  6. 9.2 Homozygous Familial Hypercholesterolemia Treatment Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Homozygous Familial Hypercholesterolemia Treatment Distributors
  9. 9.2.3 Homozygous Familial Hypercholesterolemia Treatment Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst